DK1301213T3 - Flerkomponentsystemer til biologisk transport - Google Patents
Flerkomponentsystemer til biologisk transport Download PDFInfo
- Publication number
- DK1301213T3 DK1301213T3 DK01963739.6T DK01963739T DK1301213T3 DK 1301213 T3 DK1301213 T3 DK 1301213T3 DK 01963739 T DK01963739 T DK 01963739T DK 1301213 T3 DK1301213 T3 DK 1301213T3
- Authority
- DK
- Denmark
- Prior art keywords
- gly
- positively charged
- backbone
- composition
- attached
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
- A61K49/128—Linear polymers, e.g. dextran, inulin, PEG comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nanotechnology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cell Biology (AREA)
- Obesity (AREA)
- Radiology & Medical Imaging (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
Claims (27)
1. Sammensætning, som omfatter et ikke-kovalent associationskompleks af: (a) en positivt ladet polymer rygrad, hvortil der kovalent er bundet en flerhed af positivt ladede aminosyresekvenser valgt blandt -(Gly)ni-(Arg)n2, hvor n1 er et heltal fra 0 til 20, og n2 er et ulige heltal fra 5 til 25; (Gly)p-RGRDDRRQRRR-(Gly)q eller (Gly)p-YGRKKRRQRRR-(Gly)q, hvor indekserne p og q hver uafhængigt er et heltal fra 0 til 20; og et positivt ladet HIV-TAT-peptiddomæne; og (b) mindst to elementer valgt fra gruppen bestående af: i) en første negativt ladet rygrad, hvortil der er bundet en flerhed af billeddannelseselementer; ii) en anden negativt ladet rygrad, hvortil der er bundet en flerhed af målsøgningsmidler; og iii) en tredje negativt ladet rygrad, hvortil der er bundet en flerhed af biologiske midler; hvor hvert af de biologiske midler er et terapeutisk eller kosmeceutisk middel valgt fra gruppen bestående af botulinumtoksin, EGF, TGF-βΙ, insulin, VEGF, en VEGF-hæmmerog antistoffer mod VEGF; hvor det ikke-kovalente associationskompleks bærer en positiv nettoladning, og mindst ét af de to elementer fra (b) er valgt fra gruppe i) eller gruppe iii).
2. Sammensætning ifølge krav 1, som omfatter mindst tre elementer valgt fra grupperne i) til og med iii).
3. Sammensætning ifølge krav 1, hvor mindst ét element fra (b) er fra gruppe ii).
4. Sammensætning ifølge krav 3, som omfatter mindst ét element fra hver af grupperne i) og ii).
5. Sammensætning ifølge krav 3, som omfatter mindst ét element fra hver af grupperne ii) og iii).
6. Sammensætning ifølge krav 1, hvor den positivt ladede rygrad har en længde på fra ca. 1 til 4 gange de kombinerede længder af elementerne fra (b).
7. Sammensætning ifølge krav 1, hvor den positivt ladede polymere rygrad er polylysin.
8. Sammensætning ifølge krav 7, hvor den positivt ladede aminosyresekvens er (Gly)p-RGRDDRRQRRR-(Gly)q, hvor indekserne p og q hver uafhængigt er heltal på fra 0 til 20, og hvor den positivt ladede aminosyresekvens er bundet til den positivt ladede polymere rygrad via enten den C-terminale ende eller den N-terminale ende af aminosyresekvensen.
9. Sammensætning ifølge krav 8, hvor indekserne p og q hver uafhængigt er heltal på fra 0 til 8.
10. Sammensætning ifølge krav 8, hvor indekserne p og q hver uafhængigt er heltal på fra 2 til 5.
11. Sammensætning ifølge krav 7, hvor den positivt ladede aminosyresekvens er -Gly-Gly-Gly-Arg-Arg-Arg-Arg-Arg-Arg-Arg (SEQ ID NO: 1), som er kovalent bundet til den polymere polylysinrygrad.
12. Sammensætning ifølge krav 1, hvor den positivt ladede polymere rygrad er polylysin, hvortil der kovalent er bundet en flerhed af positivt ladede effektivitetsgrupper med aminosyresekvensen -(Gly)ni-(Arg)n2, hvor n1 er et heltal fra 2 til 5, og n2 er et ulige heltal fra 7 til 17.
13. Sammensætning ifølge krav 12, hvor den positivt ladede polylysi nryg rad, hvortil der er bundet mindst én effektivitetsgruppe, har en molekylvægt på 150.000 til 300.000, og hvor der til rygraden er bundet en flerhed af GlysArgz (SEQ ID NO: 1 )-effektivitetsgrupper, hvor graden af lysinmætning er fra ca. 5% til ca. 30%.
14. Sammensætning til anvendelse ved en fremgangsmåde til fremføring af et biologisk middel til en celleoverflade hos et individ, hvor sammensætningen omfatter et ikke-kovalent associationskompleks af: (a) en positivt ladet polymer rygrad, hvortil der kovalent er bundet en eller flere effektivitetsgrupper valgt blandt aminosyresekvenserne -(Gly)ni-(Arg)n2, hvor n1 er et heltal fra 0 til 20, og n2 er et ulige heltal fra ca. 5 til ca. 25; (Gly)p-RGRDDRRQRRR-(Gly)q eller (Gly)p-YGRKKRRQRRR-(Gly)q, hvor p og q hver uafhængigt er et heltal fra 0 til 20; og et positivt ladet HIV-TAT-peptiddomæne; og (b) mindst to elementer valgt fra gruppen bestående af: i) en første negativt ladet rygrad, hvortil der er bundet en flerhed af billeddannelseselementer; ii) en anden negativt ladet rygrad, hvortil der er bundet en flerhed af målsøgningsmidler; og iii) en tredje negativt ladet rygrad, hvortil der er bundet en flerhed af terapeutiske eller kosmeceutiske biologiske midler valgt fra gruppen bestående af botulinumtoksin, EGF, TGF-βΙ, insulin, VEGF, en VEGF-hæmmerog antistoffer mod VEGF; hvor det ikke-kovalente associationskompleks bærer en positiv nettoladning, og mindst ét af de to elementer fra gruppe (b) er fra gruppe iii).
15. Sammensætning ifølge krav 14, hvorfremføringsfremgangsmåden er intravenøs administration.
16. Sammensætning ifølge krav 14, hvorfremføringsfremgangsmåden er transdermal eller topisk administration.
17. Sammensætning ifølge krav 14, hvorfremføringsfremgangsmåden er administration ved anvendelse afen angioplastikballon.
18. Sammensætning ifølge krav 14, hvorfremføringsfremgangsmåden er administration ved anvendelse af et kateter.
19. Sammensætning ifølge krav 14, hvorfremføringsfremgangsmåden er intraperitoneal administration.
20. Sammensætning ifølge krav 14, hvor sammensætningen foreligger som en gelformulering.
21. Fremgangsmåde til fremstilling afen farmaceutisk sammensætning, hvilken fremgangsmåde omfatter at kombinere en positivt ladet polymer rygradskomponent, hvortil der kovalent er bundet en flerhed af positivt ladede aminosyresekvenser valgt blandt -(Gly)ni-(Arg)n2, hvor n1 er et heltal fra 0 til 20, og n2 er et ulige heltal fra 5 til 25; (Gly)p-RGRDDRRQRRR-(Gly)q eller (Gly)p-YGRKKRRQRRR-(Gly)q, hvor indekserne p og q hver uafhængigt er et heltal fra 0 til 20; og et positivt ladet HIV-TAT-peptiddomæne; og mindst to elementer valgt fra gruppen bestående af: i) en første negativt ladet rygrad, hvortil der er bundet en flerhed af billeddannelseselementer; ii) en anden negativt ladet rygrad, hvortil der er bundet en flerhed af målsøgningsmidler; og iii) en tredje negativt ladet rygrad, hvortil der er bundet en flerhed af terapeutiske midler eller kosmeceutiske midler valgt fra gruppen bestående af botulinumtoksin, EGF, TGF-βΙ, insulin, VEGF, en VEGF-hæmmer og antistoffer mod VEGF; med en farmaceutisk acceptabel bærer for at danne et ikke-kovalent associationskompleks med en positiv nettoladning, med det forbehold at mindst ét af de to elementer fra grupperne i) til og med iii) er valgt fra gruppe i) eller gruppe iii).
22. Kit til formulering afen farmaceutisk fremføringssammensætning, hvilket kit omfatter en positivt ladet polymer rygradskomponent, hvortil der kovalent er bundet en flerhed af positivt ladede aminosyresekvenser valgt blandt -(Gly)ni-(Arg)n2, hvor n1 er et heltal fra 0 til 20, og n2 er et ulige heltal fra 5 til 25; (Gly)p-RGRDDRRQRRR-(Gly)q eller (Gly)p-YGRKKRRQRRR-(Gly)q, hvor indekserne p og q hver uafhængigt er et heltal fra 0 til 20; og et positivt ladet FIIV-TAT-peptiddomæne; og mindst to elementer valgt fra gruppen bestående af: i) en første negativt ladet rygrad, hvortil der er bundet en flerhed af billeddannelseselementer; ii) en anden negativt ladet rygrad, hvortil der er bundet en flerhed af målsøgningsmidler; og iii) en tredje negativt ladet rygrad, hvortil der er bundet en flerhed af terapeutiske midler eller kosmeceutiske midler valgt fra gruppen bestående af botulinumtoksin, EGF, TGF-βΙ, insulin, VEGF, en VEGF-hæmmer og antistoffer mod VEGF; og anvisninger i at fremstille den farmaceutiske fremføringssammensætning.
23. Positivt ladet rygrad, som omfatter: (a) en positivt ladet lineær polypeptidkæde, som omfatter en polymer af aminosyrer; og (b) positivt ladede forgreningsgrupper, som er kovalent bundet til den positivt ladede lineære polypeptidkæde, hvor forgreningsgrupperne omfatter i) -(Gly)ni-(Arg)n2, hvor n1 er et heltal fra 0 til 20, og n2 er et ulige heltal fra ca. 5 til ca. 25; eller ii) et positivt ladet HIV-TAT-peptiddomæne eller mindst ét HIV-TAT-fragment med aminosyresekvensen (Gly)p-RGRDDRRQRRR -(Gly)q eller (Gly)p-YGRKKRRQRRR-(Gly)q, hvor p og q uafhængigt er et heltal fra 0 til 20, og HIV-TAT-fragmentets aminosyresekvens er bundet til den positivt ladede lineære polypeptidkæde via den C-terminale ende eller den N-terminale ende af aminosyresekvensen.
24. Positivt ladet rygrad ifølge krav 23, hvor den positivt ladede lineære polypeptidkæde omfatter polylysin med en molekylvægt på 70.000 til 300.000.
25. Positivt ladet rygrad ifølge krav 23 eller 24, som er i stand til at associere sig med en negativt ladet rygrad, hvortil der er bundet et eller flere biologiske midler; hvor hvert af de biologiske midler er et terapeutisk eller kosmeceutisk middel valgt fra gruppen bestående af botulinumtoksin, EGF, TGF-βΙ, insulin, VEGF, en VEGF-hæmmer og antistoffer mod VEGF, til anvendelse ved en fremgangsmåde til fremføring af det biologiske middel til et væv eller en celle.
26. Positivt ladet rygrad ifølge et hvilket som helst af kravene 23 til 25, hvor forgreningsgrupperne, som er bundet til den positivt ladede polypeptidkæde, omfatter HIV-TAT-fragmentet med aminosyresekvensen (Gly)p-RGRDDRRQRRR-(Gly)q, hvor p og q uafhængigt er et heltal fra 0 til 20.
27. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 14, eller 15 til 20, hvor der til den positivt ladede polymere rygrad kovalent er bundet en eller flere effektivitetsgrupper med aminosyresekvensen (Gly)p-RGRDDRRQRRR-(Gly)q; hvor p og q hver uafhængigt er et heltal fra 0 til 20.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22024400P | 2000-07-21 | 2000-07-21 | |
PCT/US2001/023072 WO2002007773A2 (en) | 2000-07-21 | 2001-07-20 | Multi-component biological transport systems |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1301213T3 true DK1301213T3 (da) | 2017-03-27 |
Family
ID=22822714
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10013135.8T DK2364734T3 (da) | 2000-07-21 | 2001-07-20 | Biologiske flerkomponent-transportsystemer |
DK01963739.6T DK1301213T3 (da) | 2000-07-21 | 2001-07-20 | Flerkomponentsystemer til biologisk transport |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10013135.8T DK2364734T3 (da) | 2000-07-21 | 2001-07-20 | Biologiske flerkomponent-transportsystemer |
Country Status (13)
Country | Link |
---|---|
US (2) | US7807780B2 (da) |
EP (2) | EP2364734B1 (da) |
JP (2) | JP5610659B2 (da) |
AU (4) | AU2001284665B2 (da) |
CA (2) | CA2416289C (da) |
CY (2) | CY1118963T1 (da) |
DK (2) | DK2364734T3 (da) |
ES (1) | ES2617692T3 (da) |
IL (2) | IL154044A0 (da) |
NZ (1) | NZ523719A (da) |
PT (2) | PT2364734T (da) |
WO (1) | WO2002007773A2 (da) |
ZA (1) | ZA200300513B (da) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6239154B1 (en) | 1996-03-08 | 2001-05-29 | Adolor Corporation | Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith |
US5763445A (en) | 1996-03-08 | 1998-06-09 | Adolor Corporation | Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith |
US6750216B2 (en) | 1996-03-08 | 2004-06-15 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
US6303611B1 (en) | 1996-03-08 | 2001-10-16 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
US20080281041A1 (en) | 1999-06-07 | 2008-11-13 | Rozema David B | Reversibly Masked Polymers |
US7229961B2 (en) | 1999-08-24 | 2007-06-12 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
EP1235914A2 (en) * | 1999-11-24 | 2002-09-04 | Joseph Rosenecker | Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells |
US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
DK2364734T3 (da) | 2000-07-21 | 2017-10-30 | Revance Therapeutics Inc | Biologiske flerkomponent-transportsystemer |
AU2003216389A1 (en) * | 2002-02-21 | 2003-09-09 | Essentia Biosystems, Inc. | Induction of hair growth with vascular endothelial growth factor |
US7635463B2 (en) | 2002-02-27 | 2009-12-22 | Pharmain Corporation | Compositions for delivery of therapeutics and other materials |
DE60335608D1 (de) | 2002-02-27 | 2011-02-17 | Pharmain Corp | Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung |
US20050260259A1 (en) | 2004-04-23 | 2005-11-24 | Bolotin Elijah M | Compositions for treatment with glucagon-like peptide, and methods of making and using the same |
US20040009180A1 (en) | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
US7714015B2 (en) * | 2003-08-07 | 2010-05-11 | Lil Brat Pharmaceuticals Of Marlette, Mi | Method and composition for treating sunburned skin |
DE10355559A1 (de) * | 2003-11-21 | 2005-06-23 | Orthogen Ag | Transskin |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US8974774B2 (en) * | 2004-03-03 | 2015-03-10 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
HUE025656T2 (en) * | 2004-03-03 | 2016-04-28 | Revance Therapeutics Inc | Topical application of botulotoxins and transdermal delivery |
AU2011202928B2 (en) * | 2004-03-03 | 2013-01-10 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
ZA200707352B (en) | 2005-03-03 | 2009-04-29 | Revance Therapeutics Inc | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
NZ560799A (en) | 2005-03-03 | 2009-10-30 | Revance Therapeutics Inc | Compositions and methods for topical application and transdermal delivery of an oligopeptide |
JP2009520040A (ja) | 2005-12-19 | 2009-05-21 | ファーマイン コーポレーション | 治療薬の送達のための疎水性コアの担体組成物、及び同担体組成物の作製法及び使用法 |
US8273867B2 (en) * | 2006-02-10 | 2012-09-25 | The Regents Of The University Of California | Transducible delivery of siRNA by dsRNA binding domain fusions to PTD/CPPS |
US8454935B2 (en) * | 2006-07-12 | 2013-06-04 | Case Western Reserve University | Cell permeable probe |
CN102614528B (zh) * | 2006-08-18 | 2014-02-26 | 箭头研究公司 | 用于体内递送多核苷酸的多缀合物 |
US20100021502A1 (en) * | 2006-12-28 | 2010-01-28 | Waugh Jacob M | Compositions and Methods of Topical Application and Transdermal Delivery of Botulinum Toxins Stabililzed with Polypeptide Fragments Derived from HIV-TAT |
AU2007340162B2 (en) * | 2006-12-29 | 2013-08-01 | Revance Therapeutics, Inc. | Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from HIV-TAT |
KR101722038B1 (ko) | 2007-07-26 | 2017-04-03 | 레반스 테라퓨틱스, 아이엔씨. | 항미생물 펩티드, 조성물, 및 이용 방법 |
US7960336B2 (en) | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
US8563527B2 (en) | 2007-08-20 | 2013-10-22 | Pharmain Corporation | Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same |
US20090176892A1 (en) | 2008-01-09 | 2009-07-09 | Pharmain Corporation | Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same |
SG2014009112A (en) | 2008-03-14 | 2014-04-28 | Allergan Inc | Immuno-based botulinum toxin serotype a activity assays |
KR102005930B1 (ko) * | 2008-12-31 | 2019-07-31 | 레반스 테라퓨틱스, 아이엔씨. | 주사용 보툴리눔 독소 제제 |
BRPI1015938A2 (pt) | 2009-06-25 | 2016-09-27 | Revance Therapeutics Inc | formulações da toxina botulínica livre de albumina |
CN102666396B (zh) * | 2009-10-21 | 2015-05-13 | 雷文斯治疗公司 | 用于纯化非复合的肉毒杆菌神经毒素的方法和系统 |
US9623117B2 (en) * | 2011-04-04 | 2017-04-18 | Wisconsin Alumni Research Foundation | Method for selective targeting and entry of bacterial toxins to cells |
IN2015DN01765A (da) | 2012-08-20 | 2015-05-29 | Univ California | |
US20140120077A1 (en) | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions and Methods for Safe Treatment of Rhinitis |
JP6912887B2 (ja) * | 2013-12-12 | 2021-08-04 | ライフ テクノロジーズ コーポレーション | トランスフェクションの強化のための膜透過性ペプチドならびにそれらを使用する組成物及び方法 |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
US10501564B2 (en) * | 2015-02-27 | 2019-12-10 | Josho Gakuen Educational Foundation | Polymer compound which has membrane-permeable peptide in side chain |
KR101666934B1 (ko) * | 2015-03-05 | 2016-10-17 | 한국유니온제약 주식회사 | 개량형 TAT 펩타이드가 융합된 EGF, 티모신β4, hGH 단백질의 생산방법 및 이들 단백질을 포함하는 화장료 조성물 |
KR101993844B1 (ko) * | 2016-07-20 | 2019-06-27 | 한국유니온제약 주식회사 | 개량형 TAT 펩타이드가 융합된 EGF 또는 hGH 단백질의 생산방법 및 이들 단백질을 포함하는 화장료 조성물 |
EP3675900A4 (en) | 2017-08-28 | 2021-05-05 | Revance Therapeutics, Inc. | TRANSMUCOSAL BOTULINUM TOXIN COMPOSITIONS, KITS, AND METHODS FOR TREATMENT OF BLADDER DISORDER |
EP3753568A1 (en) | 2019-06-21 | 2020-12-23 | Fastox Pharma SA | Composition modulating botulinum neurotoxin effect |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4434228A (en) * | 1982-04-20 | 1984-02-28 | Genex Corporation | Immobilization of biological materials in condensed polyalkyleneimine polymers |
CA1341091C (en) | 1983-10-20 | 2000-09-05 | Masayori Inouye | Regulation of gene expression by employing translational inhibition utilizaing mrna interfering complementary rna |
FR2573436B1 (fr) | 1984-11-20 | 1989-02-17 | Pasteur Institut | Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins |
US4816568A (en) * | 1986-05-16 | 1989-03-28 | International Minerals & Chemical Corp. | Stabilization of growth hormones |
FR2602790B1 (fr) | 1986-08-13 | 1990-06-01 | Transgene Sa | Expression d'un antigene specifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement preventif ou curatif de la tumeur correspondante |
AU632993B2 (en) | 1987-12-15 | 1993-01-21 | Gene Shears Pty. Limited | Ribozymes |
US5420105A (en) * | 1988-09-23 | 1995-05-30 | Gustavson; Linda M. | Polymeric carriers for non-covalent drug conjugation |
US5252713A (en) * | 1988-09-23 | 1993-10-12 | Neorx Corporation | Polymeric carriers for non-covalent drug conjugation |
US5744166A (en) * | 1989-02-25 | 1998-04-28 | Danbiosyst Uk Limited | Drug delivery compositions |
US5804604A (en) * | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
US5747641A (en) * | 1989-12-21 | 1998-05-05 | Biogen Inc | Tat-derived transport polypeptide conjugates |
US5629020A (en) * | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
WO1992007871A1 (en) | 1990-10-24 | 1992-05-14 | Allelix Biopharmaceuticals Inc. | Peptide-based inhibitors of hiv replication |
US5190873A (en) * | 1991-06-21 | 1993-03-02 | California Institute Of Biological Research | Hybrid tryptophan aporepressor containing ligand binding sites |
GB9120306D0 (en) * | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
US5607691A (en) * | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
ES2123062T3 (es) * | 1992-08-21 | 1999-01-01 | Biogen Inc | Polipeptidos de transporte derivados de la proteina tat. |
US5877278A (en) * | 1992-09-24 | 1999-03-02 | Chiron Corporation | Synthesis of N-substituted oligomers |
US5709861A (en) * | 1993-04-22 | 1998-01-20 | Emisphere Technologies, Inc. | Compositions for the delivery of antigens |
US6974578B1 (en) * | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
US5766605A (en) * | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
NO180167C (no) * | 1994-09-08 | 1997-02-26 | Photocure As | Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol |
US5484720A (en) * | 1994-09-08 | 1996-01-16 | Genentech, Inc. | Methods for calcium phosphate transfection |
US6232295B1 (en) * | 1994-10-12 | 2001-05-15 | Jon Faiz Kayyem | Cell-specific contrast agent and gene delivery vehicles |
US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
US5756468A (en) * | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
US5795587A (en) * | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
GB9600272D0 (en) * | 1996-01-06 | 1996-03-06 | Univ Nottingham | Polymers |
CA2252706A1 (en) | 1996-05-01 | 1997-11-06 | Antivirals Inc. | Polypeptide conjugates for transporting substances across cell membranes |
GB9623051D0 (en) | 1996-11-06 | 1997-01-08 | Schacht Etienne H | Delivery of DNA to target cells in biological systems |
FR2755976B1 (fr) | 1996-11-15 | 1999-01-15 | Idm Immuno Designed Molecules | Nouveaux complexes d'acides nucleiques et de polymere substitue par des residus entrainant la destabilisation des membranes cellulaires |
US5794496A (en) | 1996-12-05 | 1998-08-18 | Hand Tool Design Corporation | Pawl module for ratchet wrench |
US6743521B2 (en) * | 1997-04-21 | 2004-06-01 | California Institute Of Technology | Multifunctional polymeric tissue coatings |
ES2210761T3 (es) * | 1997-05-21 | 2004-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas. |
AU1387299A (en) * | 1997-11-12 | 1999-05-31 | Valentis, Inc. | Expression plasmids for multiepitope nucleic acid-based vaccines |
US5985434A (en) * | 1997-11-25 | 1999-11-16 | Kimberly-Clark Worldwide, Inc. | Absorbent foam |
JP2002505077A (ja) * | 1997-12-10 | 2002-02-19 | ワシントン大学 | 抗病原体システムおよびその使用方法 |
WO1999042091A2 (en) * | 1998-02-19 | 1999-08-26 | Massachusetts Institute Of Technology | Use of polycations as endosomolytic agents |
US6011646A (en) | 1998-02-20 | 2000-01-04 | The Regents Of The Unviersity Of California | Method to adjust multilayer film stress induced deformation of optics |
FR2777890B1 (fr) * | 1998-04-22 | 2000-12-29 | Roussy Inst Gustave | Composes peptidiques d'hsp70 utiles dans l'immunotherapie du cancer |
US6261679B1 (en) * | 1998-05-22 | 2001-07-17 | Kimberly-Clark Worldwide, Inc. | Fibrous absorbent material and methods of making the same |
BR9912070A (pt) * | 1998-07-13 | 2001-04-10 | Expression Genetics Inc | Análogo de poliéster de poli-l-lisina como um solúvel, veìculo de distribuição de gene biodegradável |
US6280937B1 (en) * | 1998-08-14 | 2001-08-28 | Rigel Pharmaceuticals, Inc. | Shuttle vectors |
BR9914891A (pt) | 1998-10-27 | 2001-07-17 | Mayo Foundation | Processos para aperfeiçoamento de cura de ferimento |
ES2213397T3 (es) * | 1998-12-02 | 2004-08-16 | I.D.M. Immuno-Designed Molecules | Nuevos conjugados oligomericos capaces de transferir moleculas biologicas a las celulas. |
AU2172800A (en) | 1998-12-10 | 2000-06-26 | Washington University | Protein transduction system and methods of use thereof |
WO2000034468A2 (en) * | 1998-12-11 | 2000-06-15 | Biomira Inc. | Muc-1 antagonists and methods of treating immune disorders |
US7056656B1 (en) * | 1999-01-25 | 2006-06-06 | University Of Medicine And Dentistry Of New Jersey | Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA |
ES2160485B1 (es) | 1999-04-23 | 2002-05-16 | Lipotec Sa | Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen. |
US20030236214A1 (en) * | 1999-06-09 | 2003-12-25 | Wolff Jon A. | Charge reversal of polyion complexes and treatment of peripheral occlusive disease |
EP1074625A3 (en) * | 1999-06-14 | 2002-01-02 | Pfizer Products Inc. | DNA vaccine against feline immunodeficiency virus |
US6492152B1 (en) * | 1999-06-15 | 2002-12-10 | The Board Of Regents Of The University Of Oklahoma | Core 1 β3-galactosyl transferases and methods of use thereof |
US7008924B1 (en) * | 1999-07-21 | 2006-03-07 | Amgen, Inc. | VGF fusion polypeptides |
US7229961B2 (en) * | 1999-08-24 | 2007-06-12 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into ocular tissues |
US6669951B2 (en) * | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
WO2001013957A2 (en) | 1999-08-24 | 2001-03-01 | Cellgate, Inc. | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
US6730293B1 (en) * | 1999-08-24 | 2004-05-04 | Cellgate, Inc. | Compositions and methods for treating inflammatory diseases of the skin |
US20030104622A1 (en) * | 1999-09-01 | 2003-06-05 | Robbins Paul D. | Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses |
CA2383743A1 (en) * | 1999-09-03 | 2001-03-15 | The University Of Iowa Research Foundation | Quorum sensing signaling in bacteria |
US6297056B1 (en) * | 1999-10-12 | 2001-10-02 | Pioneer Hi-Bred International, Inc. | Brassica transformation via microprojectile bombardment |
US6610820B1 (en) * | 1999-10-12 | 2003-08-26 | University Of Lausanne | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US6511676B1 (en) * | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
US6844324B1 (en) * | 1999-11-12 | 2005-01-18 | Massachusetts Institute Of Technology | Modular peptide mediated intracellular delivery system and uses therefore |
US7070807B2 (en) * | 1999-12-29 | 2006-07-04 | Mixson A James | Branched histidine copolymers and methods for using same |
US20030118598A1 (en) * | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
US20020009491A1 (en) | 2000-02-14 | 2002-01-24 | Rothbard Jonathan B. | Compositions and methods for enhancing drug delivery across biological membranes and tissues |
US6670322B2 (en) * | 2000-06-01 | 2003-12-30 | Wisconsin Alumni Research Foundation | Method of targeting pharmaceuticals to motor neurons |
US20040033241A1 (en) * | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
US6306423B1 (en) * | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
DE60032467T2 (de) * | 2000-06-14 | 2007-10-11 | Eads Astrium S.A.S. | Verfahren und System für Video-auf-Anfrage |
US7491799B2 (en) * | 2000-07-21 | 2009-02-17 | Allergan, Inc. | Modified botulinum neurotoxins |
DK2364734T3 (da) | 2000-07-21 | 2017-10-30 | Revance Therapeutics Inc | Biologiske flerkomponent-transportsystemer |
US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
US6696038B1 (en) * | 2000-09-14 | 2004-02-24 | Expression Genetics, Inc. | Cationic lipopolymer as biocompatible gene delivery agent |
US6831059B2 (en) * | 2000-10-20 | 2004-12-14 | Allergan, Inc. | Compositions and methods for treating gonadotrophin related illnesses |
CA2437983C (en) | 2001-02-16 | 2011-10-25 | Cellgate, Inc. | Transporters comprising spaced arginine moieties |
US20030086256A1 (en) | 2001-11-02 | 2003-05-08 | Heart Linked Corporation Ltd | Compact light weight energy-efficient illumination module for integrated portable applications |
US7060498B1 (en) * | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
JP2005538035A (ja) * | 2001-12-11 | 2005-12-15 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | グアニジニウム輸送試薬および結合体 |
WO2003102166A2 (en) * | 2002-02-26 | 2003-12-11 | Maxygen, Inc. | Novel flavivirus antigens |
US20030215395A1 (en) * | 2002-05-14 | 2003-11-20 | Lei Yu | Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
US7459164B2 (en) * | 2002-05-28 | 2008-12-02 | Botulinum Toxin Research Associates, Inc. | Composition for therapeutic and cosmetic botulinum toxin |
WO2003101484A1 (en) * | 2002-05-31 | 2003-12-11 | Thomas Jefferson University | Compositions and methods for transepithelial molecular transport |
US20040009180A1 (en) * | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
US7071167B2 (en) * | 2002-11-13 | 2006-07-04 | L'oreal | Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines |
US6866856B2 (en) * | 2002-12-31 | 2005-03-15 | Avon Products, Inc. | Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis |
US7482016B2 (en) * | 2003-03-19 | 2009-01-27 | The J. David Gladstone Institutes | Immunogenic compositions comprising HIV-1 acetylated Tat polypeptides |
WO2004084839A2 (en) * | 2003-03-24 | 2004-10-07 | Cady Roger K | Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin |
WO2004084905A2 (en) * | 2003-03-24 | 2004-10-07 | University Of Florida | Use of 5-ht2c receptor activity affecting compounds for treating idiopathic hyperhidrosis and associated conditions |
US8974774B2 (en) * | 2004-03-03 | 2015-03-10 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
HUE025656T2 (en) * | 2004-03-03 | 2016-04-28 | Revance Therapeutics Inc | Topical application of botulotoxins and transdermal delivery |
US7691381B2 (en) * | 2004-04-15 | 2010-04-06 | Allergan, Inc. | Stabilized biodegradable neurotoxin implants |
US20060040882A1 (en) * | 2004-05-04 | 2006-02-23 | Lishan Chen | Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
CA2578250C (en) * | 2004-07-26 | 2013-03-05 | Merz Pharma Gmbh & Co. Kgaa | Therapeutic composition with a botulinum neurotoxin |
US20060024331A1 (en) * | 2004-08-02 | 2006-02-02 | Ester Fernandez-Salas | Toxin compounds with enhanced membrane translocation characteristics |
ZA200707352B (en) * | 2005-03-03 | 2009-04-29 | Revance Therapeutics Inc | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
-
2001
- 2001-07-20 DK DK10013135.8T patent/DK2364734T3/da active
- 2001-07-20 WO PCT/US2001/023072 patent/WO2002007773A2/en active IP Right Grant
- 2001-07-20 CA CA2416289A patent/CA2416289C/en not_active Expired - Fee Related
- 2001-07-20 EP EP10013135.8A patent/EP2364734B1/en not_active Expired - Lifetime
- 2001-07-20 EP EP01963739.6A patent/EP1301213B1/en not_active Expired - Lifetime
- 2001-07-20 PT PT100131358T patent/PT2364734T/pt unknown
- 2001-07-20 PT PT1963739T patent/PT1301213T/pt unknown
- 2001-07-20 AU AU2001284665A patent/AU2001284665B2/en not_active Ceased
- 2001-07-20 ES ES01963739.6T patent/ES2617692T3/es not_active Expired - Lifetime
- 2001-07-20 NZ NZ523719A patent/NZ523719A/en not_active IP Right Cessation
- 2001-07-20 JP JP2002513506A patent/JP5610659B2/ja not_active Expired - Fee Related
- 2001-07-20 DK DK01963739.6T patent/DK1301213T3/da active
- 2001-07-20 AU AU8466501A patent/AU8466501A/xx active Pending
- 2001-07-20 IL IL15404401A patent/IL154044A0/xx unknown
- 2001-07-20 CA CA2797652A patent/CA2797652C/en not_active Expired - Lifetime
- 2001-07-20 US US09/910,432 patent/US7807780B2/en not_active Expired - Fee Related
-
2003
- 2003-01-20 ZA ZA200300513A patent/ZA200300513B/en unknown
- 2003-01-20 IL IL154044A patent/IL154044A/en active IP Right Grant
-
2006
- 2006-09-08 AU AU2006209264A patent/AU2006209264A1/en not_active Abandoned
-
2009
- 2009-12-24 AU AU2009253761A patent/AU2009253761B2/en not_active Expired
-
2010
- 2010-10-04 US US12/897,188 patent/US20110020229A1/en not_active Abandoned
-
2011
- 2011-12-07 JP JP2011268234A patent/JP5797104B2/ja not_active Expired - Lifetime
-
2017
- 2017-03-16 CY CY20171100331T patent/CY1118963T1/el unknown
- 2017-11-08 CY CY20171101168T patent/CY1119742T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DK2364734T3 (da) | 2017-10-30 |
AU2009253761A1 (en) | 2010-02-04 |
NZ523719A (en) | 2004-11-26 |
JP2012097094A (ja) | 2012-05-24 |
JP2004513075A (ja) | 2004-04-30 |
EP2364734A1 (en) | 2011-09-14 |
WO2002007773A3 (en) | 2003-01-30 |
IL154044A (en) | 2008-11-03 |
WO2002007773A2 (en) | 2002-01-31 |
CY1119742T1 (el) | 2018-06-27 |
IL154044A0 (en) | 2003-07-31 |
AU2001284665B2 (en) | 2006-06-08 |
US20110020229A1 (en) | 2011-01-27 |
US20030229034A1 (en) | 2003-12-11 |
AU2006209264A1 (en) | 2006-09-28 |
AU8466501A (en) | 2002-02-05 |
ES2617692T3 (es) | 2017-06-19 |
CA2416289A1 (en) | 2002-01-31 |
EP1301213A2 (en) | 2003-04-16 |
EP1301213B1 (en) | 2017-01-18 |
US7807780B2 (en) | 2010-10-05 |
ZA200300513B (en) | 2004-01-22 |
CA2416289C (en) | 2012-12-04 |
CY1118963T1 (el) | 2018-01-10 |
JP5797104B2 (ja) | 2015-10-21 |
JP5610659B2 (ja) | 2014-10-22 |
PT1301213T (pt) | 2017-04-19 |
CA2797652C (en) | 2016-03-08 |
AU2009253761B2 (en) | 2011-11-24 |
EP2364734B1 (en) | 2017-09-06 |
PT2364734T (pt) | 2017-10-04 |
CA2797652A1 (en) | 2002-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1301213T3 (da) | Flerkomponentsystemer til biologisk transport | |
AU2001284665A1 (en) | Multi-component Biological Transport Systems | |
US20210069224A1 (en) | Compositions and Methods for Topical and Diagnostic and Therapeutic Transport | |
Ulbrich et al. | Structural and chemical aspects of HPMA copolymers as drug carriers | |
Tian et al. | Biodegradable synthetic polymers: Preparation, functionalization and biomedical application | |
US20040220100A1 (en) | Multi-component biological transport systems | |
WO2006003731A1 (ja) | 高分子ミセル型mri造影剤 | |
ES2640613T3 (es) | Sistemas de transporte de agentes biológicos de múltiples componentes | |
Andrew MacKay et al. | HIV TAT protein transduction domain mediated cell binding and intracellular delivery of nanoparticles | |
Xu | Design, Synthesis and Evaluation of Innovative Carriers for Delivery of MR Contrast Agents and Nucleic Acids |